Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Nuvation Bio (NUVB-WT) Other Non-Current Liabilities (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $1.7 million as the latest value for Q3 2025.

  • Quarterly Other Non-Current Liabilities rose 91.41% to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, up 91.41% year-over-year, with the annual reading at $2.1 million for FY2024, 481.59% up from the prior year.
  • Other Non-Current Liabilities for Q3 2025 was $1.7 million at Nuvation Bio, down from $2.4 million in the prior quarter.
  • The five-year high for Other Non-Current Liabilities was $2.8 million in Q1 2025, with the low at $353000.0 in Q4 2023.
  • Average Other Non-Current Liabilities over 3 years is $1.4 million, with a median of $1.4 million recorded in 2024.
  • Peak annual rise in Other Non-Current Liabilities hit 481.59% in 2024, while the deepest fall reached 48.25% in 2024.
  • Over 3 years, Other Non-Current Liabilities stood at $353000.0 in 2023, then surged by 481.59% to $2.1 million in 2024, then dropped by 15.34% to $1.7 million in 2025.
  • According to Business Quant data, Other Non-Current Liabilities over the past three periods came in at $1.7 million, $2.4 million, and $2.8 million for Q3 2025, Q2 2025, and Q1 2025 respectively.